Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

6.7%

1 terminated/withdrawn out of 15 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
7(46.7%)
Phase 2
6(40.0%)
Phase 3
2(13.3%)
15Total
Phase 1(7)
Phase 2(6)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials
NCT07554196Phase 1Completed

A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors

Role: lead

NCT07547553Phase 1Not Yet Recruiting

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

Role: lead

NCT07499544Phase 3Not Yet Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)

Role: lead

NCT07519330Phase 2Not Yet Recruiting

Clinical Study to Evaluate the Efficacy and Safety of HH-006 in Patients With Chronic Hepatitis B Virus Infection

Role: lead

NCT05861674Phase 2Completed

A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

Role: lead

NCT05734807Phase 2Completed

A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia

Role: lead

NCT05787418Phase 3Enrolling By Invitation

HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2

Role: lead

NCT05713318Phase 2Completed

A Study To Assess The Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19

Role: lead

NCT05674448Phase 2Terminated

A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection

Role: lead

NCT05839639Phase 2Completed

A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors

Role: lead

NCT05753878Phase 1Completed

A Study to Evaluate the Safety and Pharmacokinetics of HH-120 Nasal Spray in Healthy Volunteers

Role: lead

NCT05116865Phase 1Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled HH-120 Aerosol in Healthy Volunteers

Role: lead

NCT06039163Phase 1Completed

A Study to Assess the Safety, Tolerability and Preliminary Efficacy of HH-120 for the Treatment of COVID-19

Role: lead

NCT05275465Phase 1Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers

Role: lead

NCT05542979Phase 1Completed

A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection

Role: lead

All 15 trials loaded